Poly(L-lactide) nanoparticles reduce amphotericin B cytotoxicity and maintain its in vitro antifungal activity

Journal of Nanoscience and Nanotechnology

Volumn 15, Issue 1, 2015, Pages 848-854

  Casa, Diani Meza ^a   Carraro, Talita Cristina Moreira Moraes ^a   De Camargo, Luciana Erzinger Alves ^a   Dalmolin, Luciana Facco ^a   Khalil, Najeh Maissar ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

Author keywords

Amphotericin B; Candida albicans; Candida tropicalis; Hemolysis; Nanoparticles; Poly(lactide)

Indexed keywords

BLOOD; CANDIDA; EMULSIFICATION; ENCAPSULATION; PARTICLE SIZE; YEAST;

AMPHOTERICIN B; CANDIDA ALBICANS; CANDIDA TROPICALIS; HEMOLYSIS; POLY LACTIDE;

NANOPARTICLES;

AMPHOTERICIN B; ANTIFUNGAL AGENT; NANOPARTICLE; POLYESTER; POLYLACTIDE;

CANDIDA; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; HEMOLYSIS; HUMAN; MICROBIAL VIABILITY; PARTICLE SIZE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; ERYTHROCYTES; HEMOLYSIS; HUMANS; MICROBIAL VIABILITY; NANOPARTICLES; PARTICLE SIZE; POLYESTERS;

EID: 84920545747     PISSN: 15334880     EISSN: 15334899     Source Type: Journal    
DOI: 10.1166/jnn.2015.9177     Document Type: Article

References (37)

1. J. F. Lacerda and C. M. Oliveira, Clin. Drug Investig. 33, S5 (2013).
2. D. W. Denning and W. W. Hope, Trends Microbiol. 18, 195 (2010).
3. B. J. Kullberg and B. C. Pauw, Neth. J. Med. 55, 118 (1999).
4. N. Gold, H. A. Stout, J. F. Pagano, and R. Donovick, Antibiot. Annu. 3, 579 (1956).
5. E. Gerbaud, F. Tamion, C. Girault, K. Clabault, S. Lepretre, J. Leroy, and G. Bonmarchand, J. Antimicrob. Chemother. 51, 473 (2003).
6. D. E. Varlam, M. M. Siddiq, L. A. Parton, and H. Rüssmann, Antimicrob. Agents Chemother. 45, 679 (2001).
7. M. H. Miceli and P. Chandrasekar, Infect. Drug Resist. 5, 9 (2012).
8. J. Barwicz and P. Tancrede, Chem. Phys. Lipids 85, 145 (1997).
9. P. Legrand, E. A. Romero, B. E. Cohen, and J. Bolard, Antimicrob. Agents Chemother. 36, 2518 (1992).
10. W. Huang, Z. Zhang, X. Han, J. Tang, J. Wang, S. Dong, and E. Wang, Biophys. J. 83, 3245 (2002).
11. R. Espada, S. Vales Pina, C. Alfonso, G. Rivas, M. P. Ballesteros, and J. J. Torrado, Int. J. Pharm. 361, 64 (2008).
12. H. Fukui, T. Koike, A. Saheki, S. Sonoke, Y. Tomii, and J. Seki, Int. J. Pharm. 263, 51 (2003).
13. J. P. Adler-Moore and R. T. Proffitt, Clin. Microbiol. Infect. 14, 25 (2008).
14. G. Barratt and S. Bretagne, Int. J. Nanomedicine 2, 301 (2007).
15. R. Feferbaum, V. L. J. Krebs, S. R. C. J. Santos, E. M. A. Diniz, A. L. S. Galvani, and F. A. C. Vaz, Pediatr. Res. 43, 245 (1998).
16. J. Bolard, V. Joly, and P. Yeni, J. Liposome Res. 3, 409 (1993).
17. R. M. Mainardes, M. P. D. Gremião, I. L. Brunetti, L. M. da Fonseca, and N. M. Khalil, J. Pharm. Sci. 98, 257 (2009).
18. M. L. Hans and A. M. Lowman, Curr. Opinion Sci. 6, 319 (2002).
19. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, J. Control. Release 70, 1 (2001).
20. N. M. Khalil, T. C. F. do Nascimento, D. M. Casa, L. F. Dalmolin, A. C. de Mattos, I. Hoss, M. A. Romano, and R. M. Mainardes, Colloids Surf. B Biointerfaces 101, 353 (2013).
21. C. D. Rodrigues, D. M. Casa, L. F. Dalmolin, L. E. A. de Camargo, N. M. Khalil, and R. M. Mainardes, Curr. Nanosci. 9, 594 (2013)
22. R. M. Mainardes, N. M. Khalil, T. C. M. M. Carraro, C. D. Rodrigues, D. M. Casa, and L. F. Dalmolin, Processo de obtenc¸ão de nanopartículas poliméricas contendo o fármaco anfotericina B, Brazil, Patent PI1107204, December (2011).
23. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing, Seventeenth informational supplement (M100-S17), Clinical and Laboratory Standards Institute, Wayne, PA (2007).
24. M. L. Adams and G. S. Kwon, J. Control. Release 87, 23 (2003).
25. T. Ren, N. Xu, C. Cao, W. Yuan, X. Yu, J. Chen, and J. Ren, J. Biomater. Sci. Polym. Ed. 20, 1369 (2009).
26. J. L. Italia, M. M. Yahya, D. Singh, and M. N. Ravi Kumar, Pharm. Res. 26, 1324 (2009).
27. J. L. Italia, A. Sharp, K. C. Carter, P. Warn, and M. N. Kumar, PLoS One 6, e25744 (2011).
28. N. Xu, J. Gu, Y. Zhu, H. Wen, Q. Ren, and J. Chen, Int. J. Nanomed. 6, 905 (2011).
29. H. Van de Ven, C. Paulussen, P. B. Feijens, A. Matheeussen, P. Rombaut, P. Kayaert, G. Vane de Mooter, W. Weyenberg, P. Cos, L. Maes, and A. Ludwig, J. Control. Release 161, 795 (2012).
30. W. Tiyaboonchai and N. Limpeanchob, Int. J. Pharm. 392, 142 (2007).
31. N. Limpeanchob, W. Tiyaboonchai, S. Lamlertthon, J. Viyoch, and S. Jaipan, Naresuan Univers. J. 14, 27 (2006).
32. S. Sangeetha, D. N. Venkatesh, R. Adhiyaman, K. Santhi, and B. Suresh, Trop. J. Pharm. Res. 6, 653 (2007).
33. J. P. Jain and N. Kumar, Eur. J. Pharm. Sci. 40, 456 (2010).
34. J. Siepmann, N. Faisant, J. Akiki, J. Richard, and J.-P. Benoit, J. Control. Release 96, 123 (2004).
35. S. Sant, V. Nadeau, and P. Hildgen, J. Control. Release 107, 203 (2005).
36. J. J. Minones, O. Conde, P. Dynarowicz-Latra, and M. Casas, Coll. Surf. A 270, 129 (2005).
37. Y.-L. Yang, Y.-A. Ho, H.-H. Cheng, M. Ho, and H.-T. Lo, Infect. Contr. Hosp. Epidemiol. 25, 60 (2004).